FDA Approves Novel Drug Enfortumab Vedotin for Urothelial Cancer
A new antibody drug conjugate yielded an overall response rate of 44% among patients with advanced disease who had progressed on chemotherapy and immunotherapy.
Related Articles
Home
The 18th Annual Hematologic Malignancies Demystified conference returns in 2026. Access our virtual conference and earn CME/CE credits with education from our expert faculty. Led…
Home
Medscape Oncology Presents Satellite Symposia at the Annual M eeting in Chicago, Illinois Medscape Oncology is pleased to present several live symposia at the annual…
Home
Friday, May 30, 2025 6:45 pm – 8:15 pm CT Room: International North Chicago Hilton | Chicago, IL CME Hybrid Join the Oncology Brothers together…
Advancements in Breast Cancer Treatment | PBCC 2025
Register now for the 5th Annual Perspectives in Breast Cancer Care, September 12-13, 2025 and explore groundbreaking advancements in breast cancer treatment. Stay informed with…
Advancements in Breast Cancer Treatment | PBCC 2025
Register now for the 5th Annual Perspectives in Breast Cancer Care, September 12-13, 2025 and explore groundbreaking advancements in breast cancer treatment. Stay informed with…
Advancements in Breast Cancer Treatment | PBCC 2025
Register now for the 5th Annual Perspectives in Breast Cancer Care, September 12-13, 2025 and explore groundbreaking advancements in breast cancer treatment. Stay informed with…
Building Shared Decision Making Into Advanced Prostate Cancer Care
Join us for a symposium on advanced prostate cancer (aPC) designed to encourage the exchange of ideas between leaders in the field and attendees.ModeratorNea…